Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor

Antiviral Research

Volumn 91, Issue 2, 2011, Pages 167-176

  Goethals, Olivia ^a   Van Ginderen, Marcia ^a   Vos, Ann ^a   Cummings, Maxwell D ^a   Van Der Borght, Koen ^a   Van Wesenbeeck, Liesbeth ^a   Feyaerts, Maxim ^a   Verheyen, Ann ^a   Smits, Veerle ^a   Van Loock, Marnix ^a   Hertogs, Kurt ^a   Schols, Dominique ^b   Clayton, Reginald F ^a  

^a Tibotec Virco   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

HIV 1; Integrase; MK 2048; Raltegravir; Resistance

Indexed keywords

2 [(3 CHLORO 4 FLUOROPHENYL)METHYL] 8 ETHYL 1,2,6,7,8,9 HEXAHYDRO 10 HYDROXY N,6 DIMETHYL 1,9 DIOXOPYRAZINO[1',2':1,5]PYRROLO[2,3 D]PYRIDAZINE 4 CARBOXAMIDE; 3 HYDROXY 4 OXO 4,6,7,8,9,10 HEXAHYDROPYRIMIDO[1,2 A]AZEPINE 2 CARBOXYLAMIDE; 9H PYRIDO[3,4 B]INDOLE 3 CARBOXAMIDE; ELVITEGRAVIR; INTEGRASE; INTEGRASE INHIBITOR; MK 2048; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; RALTEGRAVIR; UNCLASSIFIED DRUG; VIRUS DNA;

ARTICLE; CODON; CROSS RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CELL LINE; CODON; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; INTEGRASES; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MUTATION; PHENOTYPE; PLASMA; PYRROLIDINONES; QUINOLONES; TRANSFECTION;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN SPUMARETROVIRUS;

EID: 79959574846     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.05.011     Document Type: Article

References (54)

1. (No authors listed), 2008. Phase III trial begins for elvitegravir. AIDS Patient Care STDS 22, 762-763.
2. (No authors listed), 2009. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients. AIDS Alert 24, 106-107.
3. Anker M., Corales R.B. Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection. Expert. Opin. Investig. Drugs 2008, 17:97-103.
4. Bar-Magen T., Sloan R.D., Donahue D.A., Kuhl B.D., Zabeida A., Xu H., Oliveira M., Hazuda D.J., Wainberg M.A. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J. Virol. 2010, 84:9210-9216.
5. Belyk, K.M., Morisson, H.G., Jones, P., Summa, V., 2006. Potassium salt of an HIV integrase inhibitor. Merck, Patent WO2006060712.
6. Ceccherini-Silberstein F., Malet I., D'Arrigo R., Antinori A., Marcelin A.G., Perno C.F. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev. 2009, 11:17-29.
7. Charpentier C., Laureillard D., Piketty C., Tisserand P., Batisse D., Karmochkine M., Si-Mohamed A., Weiss L. High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors. AIDS 2010, 24:867-873.
8. Chen I.J., Neamati N., MacKerell A.D. Structure-based inhibitor design targeting HIV-1 integrase. Curr. Drug Targets Infect. Disord. 2002, 2:217-234.
9. Clavel F., Hance A.J. HIV drug resistance. N. Engl. J. Med. 2004, 350:1023-1035.
10. Cocohoba J. The SWITCHMRK studies: substitution of lopinavir/ritonavir with raltegravir in HIV-positive individuals. Expert Rev. Anti. Infect. Ther. 2009, 7:1159-1163.
11. Cooper D.A., Steigbigel R.T., Gatell J.M., Rockstroh J.K., Katlama C., Yeni P., Lazzarin A., Clotet B., Kumar P.N., Eron J.E., Schechter M., Markowitz M., Loutfy M.R., Lennox J.L., Zhao J., Chen J., Ryan D.M., Rhodes R.R., Killar J.A., Gilde L.R., Strohmaier K.M., Meibohm A.R., Miller M.D., Hazuda D.J., Nessly M.L., DiNubile M.J., Isaacs R.D., Teppler H., Nguyen B.Y. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N. Engl. J. Med. 2008, 359:355-365.
12. Da Silva, D., Pellegrin, I., Anies, G., Breilh, D., Wittkop, L., Morlat, P., Dupon, M., Neau, D., Pellegrin, J.L., Fleury, H., Masquelier, B., 2008. Mutations patterns in the HIV-1 integrase related to virological failure on raltegravir-containing regimens, XVII International HIV Drug Resistance Workshop, Sitges, Spain.
13. DeGruttola V., Dix L., D'Aquila R., Holder D., Phillips A., Ait-Khaled M., Baxter J., Clevenbergh P., Hammer S., Harrigan R., Katzenstein D., Lanier R., Miller M., Para M., Yerly S., Zolopa A., Murray J., Patick A., Miller V., Castillo S., Pedneault L., Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 2000, 5:41-48.
14. Engelman A., Craigie R. Identification of conserved amino acid residues critical for human immunodeficiency virus type 1 integrase function in vitro. J. Virol. 1992, 66:6361-6369.
15. Eron J.J., Young B., Cooper D.A., Youle M., Dejesus E., Andrade-Villanueva J., Workman C., Zajdenverg R., Fatkenheuer G., Berger D.S., Kumar P.N., Rodgers A.J., Shaughnessy M.A., Walker M.L., Barnard R.J., Miller M.D., Dinubile M.J., Nguyen B.Y., Leavitt R., Xu X., Sklar P. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010, 375:396-407.
16. Esposito D., Craigie R. HIV integrase structure and function. Adv. Virus Res. 1999, 52:319-333.
17. Goethals O., Clayton R., Van Ginderen M., Vereycken I., Wagemans E., Geluykens P., Dockx K., Strijbos R., Smits V., Vos A., Meersseman G., Jochmans D., Vermeire K., Schols D., Hallenberger S., Hertogs K. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J. Virol. 2008, 82:10366-10374.
18. Goethals O., Vos A., Van Ginderen M., Geluykens P., Smits V., Schols D., Hertogs K., Clayton R. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology 2010, 402:338-346.
19. Hare S., Gupta S.S., Valkov E., Engelman A., Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010, 464:232-236.
20. Hare S., Vos A.M., Clayton R.F., Thuring J.W., Cummings M.D., Cherepanov P. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc. Natl. Acad. Sci. USA. 2010, 107:20057-20062.
21. Hazuda D.J., Anthony N.J., Gomez R.P., Jolly S.M., Wai J.S., Zhuang L., Fisher T.E., Embrey M., Guare J.P., Egbertson M.S., Vacca J.P., Huff J.R., Felock P.J., Witmer M.V., Stillmock K.A., Danovich R., Grobler J., Miller M.D., Espeseth A.S., Jin L., Chen I.W., Lin J.H., Kassahun K., Ellis J.D., Wong B.K., Xu W., Pearson P.G., Schleif W.A., Cortese R., Emini E., Summa V., Holloway M.K., Young S.D. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. USA 2004, 101:11233-11238.
22. Hazuda D.J., Felock P., Witmer M., Wolfe A., Stillmock K., Grobler J.A., Espeseth A., Gabryelski L., Schleif W., Blau C., Miller M.D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287:646-650.
23. Horwitz J., Chua J., Noel M. Nucleosides V. The monomesylates of 1-(2'-deoxy-bèta-d-lyxofuranosyl)thymidine. J. Org. Chem. 1964, 29:2076-2078.
24. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., Schapiro J.M., Richman D.D. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009, 17:138-145.
25. Krishnan L., Li X., Naraharisetty H.L., Hare S., Cherepanov P., Engelman A. Structure-based modeling of the functional HIV-1 intasome and its inhibition. Proc. Natl. Acad. Sci. USA. 2010, 107:15910-15915.
26. Kuki, A., Li, X., Plewe, M.B., Wang, H., Zhang, J., 2005. HIV-integrase inhibitors, pharmaceutical compositions, and methods for their use. In: Agouron Pharmaceuticals, I., Patent US2005165040.
27. Kulkosky J., Jones K.S., Katz R.A., Mack J.P., Skalka A.M. Residues critical for retroviral integrative recombination in a region that is highly conserved among retroviral/retrotransposon integrases and bacterial insertion sequence transposases. Mol. Cell Biol. 1992, 12:2331-2338.
28. LaFemina R.L., Schneider C.L., Robbins H.L., Callahan P.L., LeGrow K., Roth E., Schleif W.A., Emini E.A. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J. Virol. 1992, 66:7414-7419.
29. Lataillade M., Chiarella J., Kozal M.J. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir. Ther. 2007, 12:563-570.
30. Lennox J.L., Dejesus E., Berger D.S., Lazzarin A., Pollard R.B., Ramalho Madruga J.V., Zhao J., Wan H., Gilbert C.L., Teppler H., Rodgers A.J., Barnard R.J., Miller M.D., Dinubile M.J., Nguyen B.Y., Leavitt R., Sklar P. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J. Acquir. Immune Defic. Syndr. 2010, 55:39-48.
31. Lennox J.L., DeJesus E., Lazzarin A., Pollard R.B., Madruga J.V., Berger D.S., Zhao J., Xu X., Williams-Diaz A., Rodgers A.J., Barnard R.J., Miller M.D., DiNubile M.J., Nguyen B.Y., Leavitt R., Sklar P. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009, 374:796-806.
32. Maertens G.N., Hare S., Cherepanov P. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature 2010, 468:326-329.
33. Maignan S., Guilloteau J.P., Zhou-Liu Q., Clement-Mella C., Mikol V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J. Mol. Biol. 1998, 282:359-368.
34. Malet I., Delelis O., Soulie C., Wirden M., Tchertanov L., Mottaz P., Peytavin G., Katlama C., Mouscadet J.F., Calvez V., Marcelin A.G. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J. Antimicrob. Chemother. 2009, 63:795-804.
35. McColl, D., Fransen, S., Gupta, S., Parkin, N., Margot, N., Chuck, S., Cheng, A., Miller, M., 2007. Resistance analysis of a Phase 2 study of the integrase inhibitor elvitegravir (GS-9137), 11th European Aids Conference, Madrid, Spain.
36. McColl D.J., Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res. 2010, 85:101-118.
37. Neamati N., Lin Z., Karki R.G., Orr A., Cowansage K., Strumberg D., Pais G.C., Voigt J.H., Nicklaus M.C., Winslow H.E., Zhao H., Turpin J.A., Yi J., Skalka A.M., Burke T.R., Pommier Y. Metal-dependent inhibition of HIV-1 integrase. J. Med. Chem. 2002, 45:5661-5670.
38. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N. Engl. J. Med. 1998, 338:853-860.
39. Paredes R., Clotet B. Clinical management of HIV-1 resistance. Antiviral Res. 2010, 85:245-265.
40. Pommier Y., Johnson A.A., Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discov. 2005, 4:236-248.
41. Richman D.D. HIV chemotherapy. Nature 2001, 410:995-1001.
42. Richman D.D. Antiviral drug resistance. Antiviral Res. 2006, 71:117-121.
43. Sakai H., Kawamura M., Sakuragi J., Sakuragi S., Shibata R., Ishimoto A., Ono N., Ueda S., Adachi A. Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J. Virol. 1993, 67:1169-1174.
44. Sato, A., Kobayashi, M., Yoshinaga, T., Fujiwara, T., Underwood, M., Johns, B., Foster, S., Hazen, R., Ferris, R., Brown, K., 2009. S/GSK1349572 integrase inhibitor resistance profile, 12th European AIDS conference, Cologne, Germany.
45. Sato M., Motomura T., Aramaki H., Matsuda T., Yamashita M., Ito Y., Kawakami H., Matsuzaki Y., Watanabe W., Yamataka K., Ikeda S., Kodama E., Matsuoka M., Shinkai H. Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J. Med. Chem. 2006, 49:1506-1508.
46. Schrödinger, 2009. Suite Protein Preparation Wizard; Epik version 2.0, Schrödinger, LLC, New York, NY, 2009; Impact version 5.5, Schrödinger, LLC, New York, NY, 2009; Prime version 2.1, Schrödinger, LLC, New York, NY, 2009.
47. Serrao E., Odde S., Ramkumar K., Neamati N. Raltegravir, elvitegravir, and metoogravir: the birth of " me-too" HIV-1 integrase inhibitors. Retrovirology 2009, 6:25.
48. Tang J., Maddali K., Pommier Y., Sham Y.Y., Wang Z. Scaffold rearrangement of dihydroxypyrimidine inhibitors of HIV integrase: docking model revisited. Bioorg. Med. Chem. Lett. 2010, 20:3275-3279.
49. Vacca, J.P., Wai, J.S., Fisher, T.E., Embrey, M., Hazuda, D.J., Miller, M.D., Felock, P.J., Witmer, M.V., Gabryelski, L., Lyle, T., 2007. Discovery of MK-2048: subtle changes confer unique resistance properties to a series of tricyclic hydroxypyrrole integrase strand transfer inhibitors, 4th International AIDS Society (IAS) Conference, Sydney, Australia.
50. Valkov E., Gupta S.S., Hare S., Helander A., Roversi P., McClure M., Cherepanov P. Functional and structural characterization of the integrase from the prototype foamy virus. Nucleic Acids Res. 2009, 37:243-255.
51. Van Baelen K., Rondelez E., Van Eygen V., Ariën K., Clynhens M., Van den Zegel P., Winters B., Stuyver L.J. A combined genotypic and phenotypic human immunodeficiency virus type1 recombinant virus assay for the reverse transcriptase and integrase genes. J. Virol. Methods 2009, 161:231-239.
52. van Gent D.C., Mizuuchi K., Gellert M. Similarities between initiation of V(D)J recombination and retroviral integration. Science 1996, 271:1592-1594.
53. Vandeckerckhove L. GSK-1349572, a novel integrase inhibitor for the treatment of HIV infection. Curr. Opin. Investig. Drugs 2010, 11:203-212.
54. Wai J.S., Fisher T.E., Embrey M., Egbertson M.S., Vacca J.P., Hazuda D.J., Miller M.D., Witmer M.V., Gabryelski L., Lyle T. Next Generation of Inhibitors of HIV-1 Integrase Strand Transfer Inhibitor: Structural Diversity and Resistance Profiles 2007, CROI, Los Angeles, California.